Oncology News | pharmaphorum

News

Real Chemistry hires new global chief inclusion and health e...

Global health innovation company Real Chemistry has announced the appointment of Mary Stutts to lead its diversity, equity and inclusion strategy.

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

Exelixis' Cabometyx misses survival target in liver cancer t...

Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after reporting mixed results in a phase 3 trial in liver cancer.

News

Libtayo gets a double with EU approvals in skin, lung cancer

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-

News

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

Armed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme for domvanalimab, its anti-TIGIT antibody.

News

AbbVie jumps on the BCMA train, opting into TeneoOne buy

After dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by TeneoOne, AbbVie has gone one step further – agreeing to buy the drug and the compan

News

In a class first, Merck's Keytruda extends survival in cervi...

Merck & Co's Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs.

Real Chemistry hires new global chief inclusion and health e...

Exelixis' Cabometyx misses survival target in liver cancer t...

Libtayo gets a double with EU approvals in skin, lung cancer

Arcus preps more phase 3 trials for TIGIT antibody, as Gilea...

AbbVie jumps on the BCMA train, opting into TeneoOne buy

In a class first, Merck's Keytruda extends survival in cervi...

Severino takes the helm at Sarepta after turbulent spell

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks